Key result
Switching to ezetimibe/simvastatin reduces LDL-C ~13 percentage points more than doubling atorvastatin.
RCT (n=435)
Double-blind
1:1
Answers are grounded in this paper and cite their sources.
This randomised, double-blind study evaluated the efficacy and safety of ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg tablet compared to doubling the atorvastatin (ATV) dose in hypercholesterolaemic patients with atherosclerotic or coronary heart disease (CHD). The study group included 435 male and female CHD patients (aged >or=18 years) who had not achieved their low-density lipoprotein cholesterol (LDL-C) goal of <2.50 mmol/l while on a stable dose of ATV 10 mg for >or=6 weeks. After a 1-week diet/stabilisation period, patients with LDL-C >or=2.50 mmol/l and <or=4.20 mmol/l were randomised (1:1) to EZE/SIMVA 10/20 mg/day (n = 221) or ATV 20 mg/day (n = 214) for 6 weeks. The primary efficacy objective was to determine the per cent reduction from baseline in LDL-C at week 6. EZE/SIMVA 10/20 mg produced significantly greater mean per cent changes from baseline in LDL-C compared with ATV 20 mg (-32.8 vs. -20.3%; p </= 0.001). A significantly greater proportion of patients achieved an LDL-C goal <2.50 mmol/l with EZE/SIMVA than ATV (77.9 vs. 51.9%; p <or= 0.001). Significant improvements in total cholesterol (-20.3 vs. -13.0%), non-high-density lipoprotein cholesterol (non-HDL-C) (-27.9 vs. -17.0%), apolipoprotein B (-23.4 vs. -14.7%) and HDL-C (1.8 vs. -0.4%) were observed after switching to EZE/SIMVA 10/20 mg for 6 weeks (p < 0.05 for all parameters). EZE/SIMVA 10/20 mg was generally well tolerated, with an overall safety profile similar to that of ATV 20 mg. EZE/SIMVA 10/20 mg produced superior lipid-altering efficacy by dual inhibition of cholesterol synthesis and intestinal absorption compared with doubling the dose of ATV from 10 to 20 mg.
No takes yet. Share an insight, caveat, or question.
Barrios et al. (2005) conducted an RCT in Hypercholesterolaemia with atherosclerotic or coronary heart disease (CHD) (n=435). Ezetimibe/simvastatin (EZE/SIMVA) vs. Atorvastatin (ATV) 20 mg/day was evaluated on Per cent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 6 (p=≤0.001). Switching to ezetimibe/simvastatin 10/ produced superior LDL-C reduction compared with doubling atorvastatin to at 6 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: